Trana Discovery and Southern Research Institute Prove Assay's Ability to Identify Compounds That Inhibit HIV Replication

CARY, N.C. & BIRMINGHAM, Ala.--(BUSINESS WIRE)--Trana Discovery, a drug discovery technology company, today announced that their recently-developed HIV high-throughput screening (HTS) assay designed to identify compounds that inhibit the use of transfer RNA (tRNA) by HIV has the ability to select compounds with anti-HIV bioactivity. Because tRNA is essential for HIV replication, disruption of the virus’s ability to use tRNA appears to represent a novel target for anti-HIV therapy.